cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2019-34-3-40-44cardiotomsk-811Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESФактор роста эндотелия сосудов в качестве потенциального маркера субклинического поражения органов, опосредованного артериальной гипертониейVascular endothelial growth factor as a potential marker of subclinical organ damage mediated by arterial hypertensionhttps://orcid.org/0000-0001-6824-3963ГубареваЕ. Ю.GubarevaE. Yu.

очный аспирант кафедры внутренних болезней,

443099, Самара, ул. Чапаевская, 89

Postgraduate Student, the Internal Diseases Department,

89, Chapayevskaya str., Samara, 443099

ekaterina.ju.gubareva@gmail.comhttps://orcid.org/0000-0003-1881-024XГубареваИ. В.GubarevaI. V.

д-р мед. наук, доцент кафедры внутренних болезней,

443099, Самара, ул. Чапаевская, 89

Dr. Sci. (Med.), Associate Professor, the Internal Diseases Department,

89, Chapayevskaya str., Samara, 443099

ekaterina.ju.gubareva@gmail.comСамарский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияSamara State Medical UniversityRussian Federation2019011120193434044Copyright © Губарева Е.Ю., Губарева И.В., 20192019Губарева Е.Ю., Губарева И.В.Gubareva E.Y., Gubareva I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/811

Сообщение содержит краткий обзор ключевых исследований, аргументирующий возможность использования васкулоэндотелиального фактора роста в качестве маркера с целью стратификации риска сердечно-сосудистых осложнений (ССО) у больных гипертонической болезнью (ГБ).

The authors’ report presents a brief review of the key studies, providing the reason for the use of vascular endothelial growth factor as a marker for stratification of the risk of cardiovascular complications in patients with essential hypertension.

гипертоническая болезньсердечно-сосудистый рискмаркерыVEGFфактор роста эндотелия сосудовessential hypertensioncardiovascular riskmarkersVEGFvascular endothelial growth factorПодготовка статьи осуществлялась при финансировании гранта губернатора Самарской области в области науки и техники в первом полугодии 2018 г., Самарского областного конкурса «Молодой ученый» в номинации «Аспирант», раздел «Естественные науки».The article preparation was carried out with the financing of the Grant of the Governor of the Samara Region in the field of science and technology in the first half of 2018, the Samara Regional Competition “Young Scientist” in the category “Postgraduate”, section “Natural Sciences”.ReferencesКобалава Ж.Д., Котовская Ю.В., Моисеев В.С. Артериальная гипертония. Ключи к диагностике и лечению. М.: ГЭОТАР-Медиа; 2009:864.Kobalava J.D., Kotovskaya Yu.V., Moiseev V.S. Arterial hypertension. The key to diagnosis and treatment. Moscow: GEOTAR-Media; 2009:864 (In Russ.).Кобякова О.С., Несветайло Н.Я., Ефимова Е.В., Бойков В.А. Электронный регистр больных артериальной гипертонией в Томской 40–44 области. Бюллетень сибирской медицины. 2012;3:154–160.Kobyakova O.S., Nesvetaylo N.Ya., Efimova E.V., Boykov V.A. Electronic register of patients with arterial hypertension in Tomsk region. Bulletin of Siberian Medicine. 2012;3:154–160 (In Russ.).Mancia G., de Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G. et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007;25(6):1105–1187.Mancia G., de Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G. et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 2007;25(6):1105–1187.Мангилёва Т.А. Система сосудистого эндотелиального фактора роста и артериальная гипертензия. Серце і судини. 2012;4:107–115.Mangilyova T.A. Vascular endothelial growth factor system and arterial hypertension. Sertse i sudini. 2012;4:107–115 (In Russ.).Ferroni P., Della-Morte D., Palmirotta R., Rundek T., Guadagni F., Roselli M. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies. Curr. Vasc. Pharmacol. 2012;10(4):479–493.Ferroni P., Della-Morte D., Palmirotta R., Rundek T., Guadagni F., Roselli M. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies. Curr. Vasc. Pharmacol. 2012;10(4):479–493.Хаишева Л.А., Шлык С.В., Плескачев А.С., Макаренко Е.С. Сосудистое ремоделирование при артериальной гипертонии: особенности ангиогенеза. Клиницист. 2012;1:26–30.Kaisheva L.A., Shlyk S.V., Pleskachev A.S., Makarenko E.S. Vascular remodeling in arterial hypertension: features of angiogenesis. The Clinician. 2012;1:26–30 (In Russ.).Недогода С.В., Чаляби Т.А., Цома В.В., Барыкина И.Н., Мазина Г.В., Ледяева А.А. и др. Возможности препарата Эксфорж и его комбинации с флувастатином в улучшении сосудистой эластичности у пациентов с артериальной гипертензией и высоким риском развития сердечно-сосудистых осложнений. Consilium Medicum. 2009;11(5):37−42.Nedogoda S.V., Chalyabi T.A., Coma V.V., Baryikina I.N., Mazina G.V., Ledyaeva A.A. et al. The possibilities of Exforge and its combination with fluvastatin in improving vascular elasticity in patients with hypertension and a high risk of cardiovascular complications. Consilium Medicum. 2009;11(5):37−42 (In Russ.).Peach C.J., Mignone V.W., Arruda M.A., Alcobia D.C., Hill S.J., Kilpatrick L.E. et al. Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2. Int. J. Mol. Sci. 2018;19(4):E1264. DOI: 10.3390/ijms19041264.Peach C.J., Mignone V.W., Arruda M.A., Alcobia D.C., Hill S.J., Kilpatrick L.E. et al. Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2. Int. J. Mol. Sci. 2018;19(4):E1264. DOI: 10.3390/ijms19041264.Iruela-Arispe M.L., Zovein A. Angiogenesis. Fetal and Neonatal Physiology. 2017;85–89:e2. DOI: 10.1016/b978-0-323-35214-7.00008-1.Iruela-Arispe M.L., Zovein A. Angiogenesis. Fetal and Neonatal Physiology. 2017;85–89:e2. DOI: 10.1016/b978-0-323-35214-7.00008-1.Shibuya M. VEGFR and type-V RTK activation and signaling. Cold Spring Harb. Perspect. Biol. 2013;5:a009092. DOI: 10.1101/cshperspect.a009092.Shibuya M. VEGFR and type-V RTK activation and signaling. Cold Spring Harb. Perspect. Biol. 2013;5:a009092. DOI: 10.1101/cshperspect.a009092.Wu F.T., Stefanini M.O., Mac Gabhann F., Kontos C.D., Annex B.H., Popel A.S. A systemic biology perspective on sVEGFR1: its biological function, pathogenic role & therapeutic use. Journal of Cellular and Molecular Medicine. 2010;14:528–552.Wu F.T., Stefanini M.O., Mac Gabhann F., Kontos C.D., Annex B.H., Popel A.S. A systemic biology perspective on sVEGFR1: its biological function, pathogenic role & therapeutic use. Journal of Cellular and Molecular Medicine. 2010;14:528–552.Stumpf C., Jukic J., Yilmaz A., Raaz D., Schmieder R.E., Daniel W.G. et al. Elevated VEGF-plasma levels in young patients with mild essential hypertension. Eur. J. Clin. Invest. 2009;39(1):31–36. DOI: 10.1111/j.1365-2362.2008.02056.x.Stumpf C., Jukic J., Yilmaz A., Raaz D., Schmieder R.E., Daniel W.G. et al. Elevated VEGF-plasma levels in young patients with mild essential hypertension. Eur. J. Clin. Invest. 2009;39(1):31–36. DOI: 10.1111/j.1365-2362.2008.02056.x.Коваль С.Н., Снегурская И.А., Мысниченко О.В. Cемейство васкулоэндотелиального фактора роста и его возможная роль в патогенезе артериальных гипертензий. Артериальная гипертензия. 2012;4(24):36–41.Koval S.N., Snegurskaya I.A., Myusnichenko O.V. Family of vasculoendothelial growth factor and its possible role in the pathogenesis of arterial hypertension. Arterial Hypertension. 2012;4(24):36–41 (In Russ.).Fearnley G.W., Odell A.F., Latham A.M., Mughal N.A., Bruns A.F., Burgoyne N.J. et al. VEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions. Mol. Biol. Cell. 2014;25:2509–2521.Fearnley G.W., Odell A.F., Latham A.M., Mughal N.A., Bruns A.F., Burgoyne N.J. et al. VEGF-A isoforms differentially regulate ATF-2-dependent VCAM-1 gene expression and endothelial-leukocyte interactions. Mol. Biol. Cell. 2014;25:2509–2521.Yamazaki Y., Matsunaga Y., Tokunaga Y., Obayashi S., Saito M., Morita T. Snake venom vascular endothelial growth factors (VEGF-Fs) exclusively vary their structures and functions among species. J. Biol. Chem. 2009;284:9885–9891.Yamazaki Y., Matsunaga Y., Tokunaga Y., Obayashi S., Saito M., Morita T. Snake venom vascular endothelial growth factors (VEGF-Fs) exclusively vary their structures and functions among species. J. Biol. Chem. 2009;284:9885–9891.Iyer S., Acharya K.R. Tying the knot: The cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines. FEBS Journal. 2011;278:4304–4322.Iyer S., Acharya K.R. Tying the knot: the cystine signature and molecular-recognition processes of the vascular endothelial growth factor family of angiogenic cytokines. FEBS Journal. 2011;278:4304–4322.Kennedy C.R.J. What type of VEGF do you need? JASN. 2010;21:1410– 1412.Kennedy C.R.J. What type of VEGF do you need? JASN. 2010;21:1410– 1412.Schneider B.P., Radovich M., Miller K.D. The role of vascular endothelial growth factor genetic variability in cancer. Clinical Cancer Research. 2009;15:5297–5301.Schneider B.P., Radovich M., Miller K.D. The role of vascular endothelial growth factor genetic variability in cancer. Clinical Cancer Research. 2009;15:5297–5301.Ferrara N. From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials – an interview with Napoleone Ferrara by Domenico Ribatti. Int. J. Dev. Biol. 2011;55(4–5):383– 388. DOI: 10.1387/ijdb.103216dr.Ferrara N. From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials – an interview with Napoleone Ferrara by Domenico Ribatti. Int. J. Dev. Biol. 2011;55(4–5):383– 388. DOI: 10.1387/ijdb.103216dr.Ferrara N., Adamis A.P. Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery. 2016;15:385–403.Ferrara N., Adamis A.P. Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery. 2016;15:385–403.Гавриленко Т.И., Рыжкова Н.А., Пархоменко А.Н. Сосудистый эндотелиальный фактор роста в клинике внутренних заболеваний и его патогенетическое значение. Украинский кардиологический журнал. 2011;4:87–95.Gavrilenko T.I., Ryuzhkova N.A., Parhomenko A.N. Vascular endothelial growth factor in the clinic of internal diseases and its pathogenetic significance. Ukrainian Journal of Cardiology. 2011;4:87–95 (In Russ.).Pallet N., Thervet E., Timsit M.O. Angiogenic response following renal ischemia reperfusion injury: New players. Prog. Urol. 2014:24:S20–S25.Pallet N., Thervet E., Timsit M.O. Angiogenic response following renal ischemia reperfusion injury: New players. Prog. Urol. 2014;24:S20–S25.Fiedler L. Methods in molecular biology series – VEGF signaling (Springer Protocols). Springer, Humana Press; 2015. DOI: 10.1007/978-1-4939-2917-7.Fiedler L. Methods in molecular biology series – VEGF signaling (Springer Protocols). Springer, Humana Press; 2015. DOI: 10.1007/978-1- 4939-2917-7.Xu D., Fuster M.M., Lawrence R., Esko J.D. Heparan sulfat regulates VEGF165- and VEGF121- mediated vascular hyperpermeability. J. Biol. Chem. 2011;286:737–745.Xu D., Fuster M.M., Lawrence R., Esko J.D. Heparan sulfat regulates VEGF165- and VEGF121- mediated vascular hyperpermeability. J. Biol. Chem. 2011;286:737–745.Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 2011;437:169–183. 26. Simons M., Gordon E., Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nature Reviews Molecular Cell Biology. 2016;17:611–625.Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 2011;437:169–183.Smith G.A., Fearnley G.W., Tomlinson D.C., Harrison M.A., Ponnambalam S. The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis. Biosci. Rep. 2015;35:e00253.Simons M., Gordon E., Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nature Reviews Molecular Cell Biology. 2016;17:611–625.Mac Gabhann F., Qutub A.A., Annex B.H., Popel A.S. Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. 2010;2:694–707.Smith G.A., Fearnley G.W., Tomlinson D.C., Harrison M.A., Ponnambalam S. The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis. Biosci. Rep. 2015;35:e00253.Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873–887. DOI: 10.1016/j.cell.2011.08.039.Mac Gabhann F., Qutub A.A., Annex B.H., Popel A.S. Systems biology of pro-angiogenic therapies targeting the VEGF system. Wiley Interdisciplinary Reviews: Systems Biology and Medicine. 2010;2:694–707.De Falko S. The discovery of placental growth factor and its biological activity. Expert Reviews in Molecular Medicine. 2012;44:1–9.Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146(6):873–887. DOI: 10.1016/j.cell.2011.08.039.Facemire C.S., Nixon A.B., Griffiths R., Hurwitz H., Coffman T.M. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54:652–658.De Falko S. The discovery of placental growth factor and its biological activity. Expert Reviews in Molecular Medicine. 2012;44:1–9.Granger J.P. Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors? Hypertension. 2009;54(3):465–467.Facemire C.S., Nixon A.B., Griffiths R., Hurwitz H., Coffman T.M. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54:652–658.Palmirotta R., Ferroni P., Ludovici G., Martini F., Savonarola A., D’Alessandro R. et al. VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension. Clin. Biochem. 2010;43:1090–1095.Granger J.P. Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors? Hypertension. 2009;54(3):465–467.Sobti R.C., Maithil N., Thakur H., Sharma Y., Talwar K.K. VEGF and IL-4 gene variability and its association with the risk of coronary heart disease in north Indian population. Mol. Cell. Biochem. 2010;341:139–148.Palmirotta R., Ferroni P., Ludovici G., Martini F., Savonarola A., D’Alessandro R. et al. VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension. Clin. Biochem. 2010;43:1090–1095.Cheng C., Daskalakis C., Falkner B. Alteration in capillary morphology are found in mild blood pressure elevation. J. Hypertens. 2010;28:2258–2266.Sobti R.C., Maithil N., Thakur H., Sharma Y., Talwar K.K. VEGF and IL-4 gene variability and its association with the risk of coronary heart disease in north Indian population. Mol. Cell. Biochem. 2010;341:139–148.Prior S.D., Mckenzie M.J., Joseph L.J., Ivey F.M., Macko R.F., Hafer-Macko C.E. et al. Reduced skeletal muscle capillarization and glucose intolerance. Microcirculation. 2009;16:203–212.Cheng C., Daskalakis C., Falkner B. Alteration in capillary morphology are found in mild blood pressure elevation. J. Hypertens. 2010;28:2258–2266.Feihl F., Liaudet L., Waeber B. The macrocirculation and microcirculation of hypertension. Curr. Hypertens. Rep. 2009;11(3):182–189.Prior S.D., Mckenzie M.J., Joseph L.J., Ivey F.M., Macko R.F., Hafer-Macko C.E. et al. Reduced skeletal muscle capillarization and glucose intolerance. Microcirculation. 2009;16:203–212.Tsai W.C., Li Y.H., Huang Y.Y., Lin C.C., Chao T.H., Chen J.H. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin. Sci. 2005;109:39–43.Feihl F., Liaudet L., Waeber B. The macrocirculation and microcirculation of hypertension. Curr. Hypertens. Rep. 2009;11(3):182–189.Haq I.U., Ramsay L.E., Yeo W.W., Jackson P.R., Wallis E.J. Is the Framingham risk unction valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart. 1999;81:40–46.Tsai W.C., Li Y.H., Huang Y.Y., Lin C.C., Chao T.H., Chen J.H. Plasma vascular endothelial growth factor as a marker for early vascular damage in hypertension. Clin. Sci. 2005;109:39–43.Haq I.U., Ramsay L.E., Yeo W.W., Jackson P.R., Wallis E.J. Is the Framingham risk unction valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart. 1999;81:40–46.Haq I.U., Ramsay L.E., Yeo W.W., Jackson P.R., Wallis E.J. Is the Framingham risk unction valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart. 1999;81:40–46.

The authors declare that there are no conflicts of interest present.